Recursion Pharmaceuticals (RXRX) EBIT (2020 - 2025)
Historic EBIT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$172.2 million.
- Recursion Pharmaceuticals' EBIT fell 7508.39% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 8356.81%. This contributed to the annual value of -$479.0 million for FY2024, which is 3683.48% down from last year.
- Latest data reveals that Recursion Pharmaceuticals reported EBIT of -$172.2 million as of Q3 2025, which was down 7508.39% from -$176.2 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' EBIT ranged from a high of -$30.5 million in Q1 2021 and a low of -$191.4 million during Q1 2025
- In the last 5 years, Recursion Pharmaceuticals' EBIT had a median value of -$81.7 million in 2023 and averaged -$94.6 million.
- In the last 5 years, Recursion Pharmaceuticals' EBIT crashed by 15393.85% in 2021 and then soared by 612.38% in 2022.
- Quarter analysis of 5 years shows Recursion Pharmaceuticals' EBIT stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then plummeted by 85.76% to -$183.8 million in 2024, then rose by 6.29% to -$172.2 million in 2025.
- Its last three reported values are -$172.2 million in Q3 2025, -$176.2 million for Q2 2025, and -$191.4 million during Q1 2025.